Literature DB >> 24502538

Drug resistance-related miRNAs in hepatocellular cancer.

Liu Hong1, Yu Han, Hongwei Zhang, Qingchuan Zhao, Kaichun Wu, Daiming Fan.   

Abstract

Hepatocellular cancer is a hypervascular cancer characterized by rapid progression as well as resistance to chemotherapy. Drug resistance arises from the alteration of many molecules, including oncogenes, tumor suppressor genes and miRNAs. This review evaluates the advances of drug resistance-related miRNAs in hepatocellular cancer, and analyzes the value of them as prognostic biomarkers and therapeutic targets. This review also discusses the limitations of miRNA-based therapy, and envisages future developments toward the clinical applications of drug resistance-related miRNAs.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24502538     DOI： 10.1586/17474124.2014.881713

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN： 1747-4124            Impact factor:   3.869


  7 in total

1.  Clinical characterization for proliferation and metastasis in advanced hepatocellular carcinoma patients.

Authors:  Cuirong Wei; Qijin Pan; Ka Wu; Rong Li
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Mechanism of Inactivation of Ornithine Aminotransferase by (1S,3S)-3-Amino-4-(hexafluoropropan-2-ylidenyl)cyclopentane-1-carboxylic Acid.

Authors:  Matthew J Moschitto; Peter F Doubleday; Daniel S Catlin; Neil L Kelleher; Dali Liu; Richard B Silverman
Journal:  J Am Chem Soc       Date:  2019-06-28       Impact factor: 15.419

3.  LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis.

Authors:  Yongxian Cao; Feng Zhang; Haotian Wang; Chunhua Bi; Jinpeng Cui; Fenghai Liu; Huazheng Pan
Journal:  Mol Cell Biochem       Date:  2020-09-23       Impact factor: 3.396

4.  Regulation of MRP4 Expression by circHIPK3 via Sponging miR-124-3p/miR-4524-5p in Hepatocellular Carcinoma.

Authors:  Haihong Hu; Yu Wang; Zhiyuan Qin; Wen Sun; Yanhong Chen; Jiaqi Wang; Yingying Wang; Jing Nie; Lu Chen; Sheng Cai; Lushan Yu; Su Zeng
Journal:  Biomedicines       Date:  2021-04-30

5.  Inactivators of Ornithine Aminotransferase for the Treatment of Hepatocellular Carcinoma.

Authors:  Richard B Silverman
Journal:  ACS Med Chem Lett       Date:  2021-12-09       Impact factor: 4.345

6.  Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.

Authors:  Mark Borris D Aldonza; Ji-Young Hong; Malona V Alinsug; Jayoung Song; Sang Kook Lee
Journal:  Oncotarget       Date:  2016-06-07

Review 7.  Non-coding RNA in drug resistance of hepatocellular carcinoma.

Authors:  Bisha Ding; Weiyang Lou; Liang Xu; Weimin Fan
Journal:  Biosci Rep       Date:  2018-10-09       Impact factor: 3.840
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.